NVO and VKTX stocks offer contrasting opportunities in the fast-growing obesity market, with key differences in growth, risk ...

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

Data readout from the maintenance dosing study of VK2735, the company’s investigational obesity candidate, is expected in the ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the May 2026 expiration. One of the key inputs that goes into the price an option buyer is willing to ...

Viking Therapeutics (NasdaqCM:VKTX) has begun a Phase 1 clinical trial for VK3019, a dual amylin and calcitonin receptor ...

Retail traders cited Novo CEO Mike Doustdar’s comment that Novo could afford a $20B, $30B or $40B deal if it was “worth it.” ...

Investors in Viking Therapeutics Inc (Symbol: VKTX) saw new options begin trading this week, for the December 19th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

High-rolling investors have positioned themselves bullish on Viking Therapeutics (NASDAQ:VKTX), and it's important for retail traders to take note. \This activity came to our attention today through ...

Investors with a lot of money to spend have taken a bullish stance on Viking Therapeutics (NASDAQ:VKTX). And retail traders should know. We noticed this today when the positions showed up on publicly ...